1/31/2018 | BK | Seattle Genetics gets $400 million bridge loan via Barclays, JPMorgan
|
9/16/2016 | SP | New Issue: HSBC prices $3 million of AMPS linked to basket of 20 common stocks
|
9/8/2016 | SP | HSBC plans 15-month AMPS with cap linked to basket of 20 stocks
|
7/16/2015 | SP | New Issue: UBS prices $139,759 8.85% trigger yield optimization notes linked to Seattle Genetics
|
6/1/2015 | SP | New Issue: UBS prices $1.22 million trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
5/28/2015 | SP | New Issue: UBS prices $175,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
3/27/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
12/9/2014 | SP | New Issue: UBS prices $479,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
9/23/2014 | SP | New Issue: UBS prices $209,895 8.91% trigger yield optimization notes linked to Seattle Genetics
|
9/19/2014 | SP | New Issue: UBS prices $149,976 9.06% trigger yield optimization notes linked to Seattle Genetics
|
9/12/2014 | SP | New Issue: UBS prices $210,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
9/4/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
8/29/2014 | SP | New Issue: Barclays prices $6.66 million 9% airbag yield autocallables linked to Seattle Genetics
|
8/28/2014 | SP | New Issue: UBS prices $155,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
8/26/2014 | SP | New Issue: UBS prices $366,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
8/26/2014 | SP | Barclays plans 7.5%-9.5% airbag autocallables tied to Seattle Genetics
|
8/20/2014 | SP | New Issue: UBS prices $675,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
8/18/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
8/13/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
8/8/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
7/23/2014 | SP | New Issue: UBS prices $110,000 airbag yield optimization notes linked to Seattle Genetics
|
5/1/2014 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
4/24/2014 | SP | New Issue: UBS prices $260,000 trigger phoenix autocallable optimization securities linked to Seattle Genetics
|
7/23/2009 | SS | Market Commentary: Bristol-Myers' buy narrows drug field; Noven tender opens; TransAlta offer considered risky
|
1/28/2009 | PP | New Issue: Seattle Genetics releases details on $11.45 million stock sale
|
1/28/2009 | PP | Market Commentary: SSL boosts acquisition chest; Bank of Queensland, Exact Sciences wrap deals; Seattle Genetics sells stock
|
1/27/2009 | PP | Seattle Genetics plans stock sale
|
1/24/2008 | SS | Baker Brothers buy 2.7 million shares of Seattle Genetics
|
3/1/2007 | SS | J.P. Morgan Partners, affiliates, sell some 2 million shares of Seattle Genetics Stock
|
11/16/2006 | BT | RBC gives Seattle Genetics sector perform rating
|
10/25/2006 | BT | Seattle Genetics gets sector perform by RBC
|
10/24/2006 | BT | Seattle Genetics' 2006 cash operating expenses expected at $35 million to $40 million
|
10/18/2006 | BT | Seattle Genetics continues to build pipeline
|
7/26/2006 | BT | RBC reiterates Seattle Genetics sector perform rating
|
6/22/2006 | BT | Seattle Genetics earns milestone payment from CuraGen
|
6/5/2006 | BT | Seattle Genetics rated at perform by RBC
|
6/5/2006 | BT | Seattle Genetics reports SGN-40 produces responses in non-Hodgkin's lymphoma, well tolerated
|
5/25/2006 | BT | Progenics broadens collaboration with Seattle Genetics for prostate cancer therapy
|
5/25/2006 | BT | Market Commentary: Cubist explodes ahead of Cubicin vote; Encysive advances; Seattle Genetics, Progenics gain on pact
|
5/4/2006 | BT | Seattle Genetics says SGN-30 showed antitumor response in phase 2 trial
|
4/26/2006 | BT | Market Commentary: Inspire trial launch brings buyers; Avigen players hopeful; Applera units mixed; LifeCell lifted 15%
|
4/25/2006 | BT | Seattle Genetics, Laureate Pharma form manufacturing agreement
|
4/11/2006 | BT | Seattle Genetics receives anti-CD30 patent claims
|
3/30/2006 | PP | New Issue: Seattle Genetics raises $5.9 million from direct placement of stock
|
3/30/2006 | BT | Market Commentary: Amylin zooms to new high after follow-on; Seattle Genetics dips; Kosan declines 9% on spot sale
|
3/30/2006 | BT | New Issue: Seattle Genetics raises $38.3 million in follow-on of 7.3 million shares at $5.25 each
|
3/29/2006 | BT | Market Commentary: Amylin shares up ahead of deal; Idenix off despite Novartis aid; Antigenics, cancer names higher
|
3/28/2006 | BT | Market Commentary: Advanced Magnetics gains 7%; Xoma slides; Seattle Genetics deal surfaces; Cephalon dips 2%
|
3/28/2006 | BTPP | Seattle Genetics plans 7.3 million share follow on; will also sell 1.13 million shares to Baker Brothers
|
12/13/2005 | BT | Seattle Genetics: Early data shows SGN-40, SGN-70 may be used in several B-cell malignancies, blood cancers
|
11/29/2005 | BT | Seattle Genetics begins phase 1/2 trial of SGN-40 for chronic lymphocytic leukemia
|
11/17/2005 | BT | Seattle Genetics starts trial of SGN-33 for acute myeloid leukemia, myelodysplastic syndromes
|